Chinese Journal of Tissue Engineering Research ›› 2012, Vol. 16 ›› Issue (39): 7395-7399.doi: 10.3969/j.issn.2095-4344.2012.39.035

Previous Articles     Next Articles

Alendronate plus alfacalcidol for the treatment of severe bone loss and osteoporotic fractures

Liu Feng1, Zhang Jun2, Wang Wen-xiu1, Zhang Ming-qiang1, Zhang Zhi-feng1, Hou Hai-tao1   

  1. 1Department of Orthopedics, the People's Hospital of Changyuan, Changyuan 453400, Henan Province, China
    2Department of Orthopedics, the First Affiliated Hospital of Xinxiang Medical College, Weihui 453100, Henan Province, China
  • Received:2012-05-02 Revised:2012-07-11 Online:2012-09-23 Published:2012-09-23
  • Contact: Liu Feng, Master, Attending physician, Department of Orthopedics, the People's Hospital of Changyuan, Changyuan 453400, Henan Province, China Liufeng1237891@163.com
  • About author:Liu Feng★, Master, Attending physician, Department of Orthopedics, the People's Hospital of Changyuan, Changyuan 453400, Henan Province, China Liufeng1237891@163.com

PDF

953

Abstract:

BACKGROUND: Alendronate and alfacalcidol can inhibit the bone transformation and increase bone mineral density of the patients with osteoporotic fractures.
OBJECTIVE: To investigate the effect of alendronate plus alfacalcidol for the treatment of severe bone loss and osteoporotic fractures.
METHODS: Patients with severe bone loss and osteoporotic fractures were selected, and then the patients were treated with alendronate plus alfacalcidol for 2 years.
RESULTS AND CONCLUSION: Compared with before treatment, the lumbar spine bone density of the patients was increased after treated with alendronate plus alfacalcidol (P < 0.05) followed by urine of type Ⅰ collagen N-terminal peptide levels and serum alkaline phosphatase activity decreased (P < 0.05). It confirmed that the alendronate plus alfacalcidol has good effect for the treatment of severe bone loss and osteoporotic fracture patients.

CLC Number: